Definium Therapeutics (DFTX) Net Cash Flow (2021 - 2026)

Definium Therapeutics (DFTX) has reported Net Cash Flow for 6 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 102.45% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $179.7 million (up 206.02% YoY), while the FY2025 annual figure was -$15.9 million, down 109.13% from the prior year.
• Net Cash Flow retreated to $4.7 million in Q1 2026 per DFTX's latest filing, from $237.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $237.9 million in Q4 2025 and bottomed at -$190.9 million in Q1 2025.
• Historically, Net Cash Flow has averaged $7.6 million across 5 years, with a median of -$12.6 million in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow soared 6656.87% — and 2025, when it sank 437.84%.
• Definium Therapeutics' Net Cash Flow stood at -$12.4 million in 2022, then tumbled by 44.53% to -$18.0 million in 2023, then dropped by 19.89% to -$21.5 million in 2024, then surged by 1204.15% to $237.9 million in 2025, then plunged by 98.03% to $4.7 million in 2026.
• Business Quant data shows DFTX's Net Cash Flow at $4.7 million in Q1 2026, $237.9 million in Q4 2025, and -$13.4 million in Q3 2025.